Prezentujeme vzácný případ symptomatického karcinomu urachu u mladého pacienta, který na našem pracovišti podstoupil chirurgickou excizi tumoru a je v remisi. Jedná se o vzácnou diagnózu, na kterou je ale potřeba při vyšetření pacienta s hematurií myslet.
We present a case of a young patient with a symptomatic urachal carcinoma. The patient underwent surgical resection at our department and is now in remission. Urachal cancer must be considered when examining a patient with visible hematuria.
- MeSH
- cystektomie metody MeSH
- cystoskopie metody MeSH
- diagnostické zobrazování metody MeSH
- dospělí MeSH
- hematurie diagnóza etiologie MeSH
- lidé MeSH
- nádory močového měchýře * chirurgie MeSH
- ultrasonografie metody MeSH
- urachus * chirurgie patologie MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mužské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
OBJECTIVE: To compare the value of flexible blue-light cystoscopy (BLC) vs flexible white-light cystoscopy (WLC) in the surveillance setting of non-muscle-invasive bladder cancer (NMIBC). METHODS: All major databases were searched for articles published before May 2023 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. The primary outcome was the accuracy of flexible BLC vs WLC in detecting bladder cancer recurrence among suspicious bladder lesions. RESULTS: A total of 10 articles, comprising 1634 patients, were deemed eligible for the quantitative synthesis. In the meta-analysis focusing on the detection of disease recurrence, there was no difference between flexible BLC and WLC (odds ratio [OR] 1.08, 95% confidence interval [CI] 0.82-1.41)]; the risk difference (RD) showed 1% of flexible BLC, corresponding to a number needed to treat (NNT) of 100. In the subgroup meta-analysis of detection of carcinoma in situ (CIS) only, there was again no significant difference between flexible BLC and WLC (OR 1.19, 95% CI 0.82-1.69), BLC was associated with a RD of 2% (NNT = 50). The positive predictive values for flexible BLC and WLC in detecting all types of recurrence were 72% and 66%, respectively, and for CIS they were 39% and 29%, respectively. CONCLUSION: Surveillance of NMIBC with flexible BLC could detect more suspicious lesions and consequently more tumour recurrences compared to flexible WLC, with a increase in the rate of false positives leading to overtreatment. A total of 100 and 50 flexible BLC procedures would need to be performed to find on additional tumor and CIS recurences, respectively. A risk-stratified strategy for patient selection could be considered when using flexible BLC for the surveillance of NMIBC patients.
- MeSH
- cystoskopie * metody MeSH
- invazivní růst nádoru MeSH
- lidé MeSH
- lokální recidiva nádoru MeSH
- nádory močového měchýře neinvadující svalovinu MeSH
- nádory močového měchýře * patologie diagnóza MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- přehledy MeSH
- srovnávací studie MeSH
- systematický přehled MeSH
PURPOSE: Cxbladder tests are urinary biomarker tests for detection of urothelial carcinoma. We developed enhanced Cxbladder tests that incorporate DNA analysis of 6 single nucleotide polymorphisms for the FGFR3 and TERT genes, in addition to the current 5 mRNA biomarkers and clinical risk factors. MATERIALS AND METHODS: Two multicenter, prospective studies were undertaken in: (1) U.S. patients with gross hematuria aged ≥18 years and (2) Singaporean patients with gross hematuria or microhematuria aged >21 years. All patients provided a midstream urine sample and underwent cystoscopy. Samples were retrospectively analyzed using enhanced Cxbladder-Triage (risk stratifies patients), enhanced Cxbladder-Detect (risk stratifies patients and detects positive patients), and the combination enhanced Cxbladder-Triage × Cxbladder-Detect. RESULTS: In the pooled cohort (N=804; gross hematuria: n=484, microhematuria: n=320), enhanced Cxbladder-Detect had a sensitivity of 97% (95% CI 89%-100%), specificity of 90% (95% CI 88%-92%), and negative predictive value of 99.7% (95% CI 99%-100%) for detection of urothelial carcinoma. Overall, 83% of patients were enhanced Cxbladder-Detect-negative (ie, needed no further work-up). Of 133 enhanced Cxbladder-Detect-positive patients, 59 had a confirmed tumor, of which 19 were low-grade noninvasive papillary carcinoma or papillary urothelial neoplasm of low malignant potential. In total, 40 tumors were high-grade Ta, T1-T4, Tis, including concomitant carcinoma in situ. Of the 74 patients with normal cystoscopy, 41 were positive by single nucleotide polymorphism analysis. Enhanced Cxbladder-Triage and enhanced Cxbladder-Detect had significantly better specificity than the first-generation Cxbladder tests (P < .001). CONCLUSIONS: This study in ethnically diverse patients with hematuria showed the analytical validity of the enhanced Cxbladder tests.
- MeSH
- cystoskopie MeSH
- dospělí MeSH
- hematurie etiologie genetika MeSH
- hodnocení rizik MeSH
- karcinom in situ * MeSH
- karcinom z přechodných buněk * diagnóza genetika moč MeSH
- lidé MeSH
- mladiství MeSH
- mutace MeSH
- nádorové biomarkery genetika moč MeSH
- nádory močového měchýře * diagnóza genetika moč MeSH
- prospektivní studie MeSH
- receptor fibroblastových růstových faktorů, typ 3 genetika MeSH
- retrospektivní studie MeSH
- senzitivita a specificita MeSH
- telomerasa * genetika MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- mladiství MeSH
- Publikační typ
- časopisecké články MeSH
- multicentrická studie MeSH
S cizím tělesem v močovém měchýři se setká skoro každý urolog. Na ukázku předkládám několik kazuistik z let 2018-2023.
A foreign body in the bladder is encountered by almost every urologist. Several case reports from the years 2018 to 2023 are presented.
- MeSH
- cizí tělesa * etiologie komplikace MeSH
- cystoskopie MeSH
- cystostomie MeSH
- lidé MeSH
- močový měchýř * chirurgie diagnostické zobrazování zranění MeSH
- reakce na cizí těleso chirurgie diagnostické zobrazování terapie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- kazuistiky MeSH
OBJECTIVE: To assess the association between cystoscopic findings and oncological outcomes in patients with non-muscle-invasive bladder cancer (NMIBC) given that the oncological impact of quantity and quality assessment of tumours with cystoscopy has not been well verified. METHODS: Multiple databases were queried in May 2022 for studies investigating the association of oncological outcomes, such as recurrence-free (RFS), progression-free (PFS), and cancer-specific survival (CSS), with cystoscopic findings, including multiplicity, size, and gross appearance of tumours in patients with NMIBC. RESULTS: Overall, 73 studies comprising 28 139 patients were eligible for the meta-analysis. Tumour multiplicity was associated with worse RFS (pooled hazard ratio [HR] 1.61, 95% confidence interval [CI] 1.48-1.74) and PFS (pooled HR 1.44, 95% CI 1.18-1.76) in NMIBC patients (including both Ta and T1). Tumour size (≥3 cm) was associated with worse RFS (pooled HR 1.97, 95% CI 1.69-2.30) and PFS (pooled HR 1.81, 95% CI 1.52-2.15) in NMIBC patients. In patients with T1 bladder cancer (BCa), tumour multiplicity and size (≥3 cm) were also associated with worse RFS, PFS and CSS. By contrast, among patients treated with bacillus Calmette-Guérin (BCG), tumour multiplicity was not associated with worse RFS, and tumour size (≥3 cm) was not associated with worse PFS. Sessile tumours were associated with worse RFS (pooled HR 2.14, 95% CI 1.52-3.01) and PFS (pooled HR 2.17, 95% CI 1.42-3.32) compared to pedunculated tumours. Compared to papillary tumours, solid tumours were associated with worse RFS (pooled HR 1.84, 95% CI 1.25-2.72) and PFS (pooled HR 3.06, 95% CI 2.31-4.07) in NMIBC patients, and CSS in T1 BCa patients (pooled HR 2.32, 95% CI 1.63-3.30). CONCLUSIONS: Cystoscopic findings, including tumour multiplicity, size, and gross appearance, strongly predict oncological outcomes in NMIBC patients. Cystoscopic visual features can help in the decision-making process regarding the timeliness and extent of tumour resection as well as future management such as intravesical therapy.
- MeSH
- aplikace intravezikální MeSH
- BCG vakcína terapeutické užití MeSH
- cystoskopie MeSH
- invazivní růst nádoru MeSH
- lidé MeSH
- lokální recidiva nádoru patologie MeSH
- nádory močového měchýře neinvadující svalovinu * MeSH
- nádory močového měchýře * patologie MeSH
- proporcionální rizikové modely MeSH
- retrospektivní studie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
Stejně jako ve všech oborech medicíny i v urologii ošetřujeme pacienty stále vyššího věku a s četnějšími komorbiditami. Řada našich pacientů tak má anamnézu rekonstrukčních výkonů na cévním řečišti. Setkali jsme se s komplikací u pacienta po angiochirurgické intervenci, po uzavření objemného aneuryzmatu vnitřní kyčelní tepny coilingem. V případě prezentovaného pacienta došlo po vyplnění aneuryzmatu coilingem ke vzniku píštěle mezi výdutí a močovým měchýřem a také k rozvoji hematurie. Zdrojem hematurie nebyla píštěl z již vyplněné výdutě, ale krvácení cév sliznice močového měchýře v důsledku kongesce z útlaku objemným vakem aneuryzmatu vnitřní tepny kyčelní. Diagnostika a terapie příčiny hematurie v důsledku aneuryzmatu je velmi náročná pro raritní výskyt a měl by se na ní podílet multidisciplinární tým složený z urologa, cévního chirurga a intervenčního radiologa.
As well as in other departments of medicine, also in urology, we treat much older patients with more frequent comorbidities. Many of our patients have a history of reconstructive procedures on the vascular system. We encountered a complication in a patient after angiosurgery, which included closing a large aneurysm of the internal iliac artery by coiling. In this case study, a fistula between the vascular bulge and the bladder developed after filling the aneurysm with coiling and the hematuria was presented. However, the source of hematuria was not the fistula from the already filled bulge, but the bleeding of the vessels of the bladder mucosa due to congestion from compression by a large sac of the aneurysm of the internal iliac artery. Diagnosis and therapy of the cause of hematuria due to an aneurysm is very difficult because of its rare occurrence therefore it should involve a multidisciplinary team consisting of a urologist, vascular surgeon and interventional radiologist.
- MeSH
- aneurysma ilické tepny * chirurgie patologie MeSH
- antibakteriální látky MeSH
- cystoskopie MeSH
- hematurie * diagnostické zobrazování etiologie terapie MeSH
- katetrizace močového měchýře MeSH
- lidé MeSH
- píštěl močového měchýře diagnostické zobrazování patologie MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- Publikační typ
- kazuistiky MeSH
This case-based discussion describes the management of a 66-yr-old man who presented to the emergency department with gross hematuria. His urine cytology was benign, and computed tomography (CT) with nephrographic phase revealed a 2.5 cm filling defect within the left renal pelvis and luminal narrowing in the right proximal ureter with hydronephrosis. CT showed no lymphadenopathy and no sign of metastatic disease. Cystoscopy was normal. In a progressive case-based discussion fashion, we will discuss the diagnostic and treatment options with two different perspectives: (1) guidelines-based current standard of care and (2) an outlook on future perspectives using the latest scientific advances that may soon become the standard of care. PATIENT SUMMARY: This presentation of a real-life clinical scenario will be useful in describing the current standard of care and future perspectives regarding the diagnosis and treatment of upper urinary tract tumors.
PURPOSE OF REVIEW: This review aims to analyze the current place of active surveillance (AS) in non-muscle-invasive bladder cancer (NMIBC). RECENT FINDINGS: A growing body of evidence suggests that AS protocols for pTa low-grade (TaLG) NMIBC are safe and feasible. However, current guidelines have not implemented AS due to a lack of high-quality data. Available studies included pTa tumors, with only one study excluding pT1-NMIBC. Inclusion/exclusion criteria were heterogeneously defined based on tumor volume, number of tumors, carcinoma in situ (CIS), or high-grade (HG) NMIBC. Tumor volume <10 mm and <5 lesions were used as cut-offs. Positive urinary cytology (UC) or cancer-related symptoms precluded inclusion. Surveillance within the first year consisted of quarterly cystoscopy. AS stopped upon the presence of cancer-related symptoms, change in tumor morphology, positive UC, or patient's request. With a median time on AS of 16 months, two-thirds of the patients failed AS. Progression to muscle-invasive bladder cancer (MIBC) was rare and occurred only in patients with pT1-NIMBC at inclusion. SUMMARY: AS in NMIBC is an attractive concept in the era of personalized medicine, but strong evidence is still awaited. A more precise definition of patient inclusion, follow-up, and failure criteria is required to improve its implementation in daily clinical practice.
